The emergence of SARS-CoV-2 led to pandemic spread of coronavirus disease 2019
(COVID-19), manifesting with respiratory symptoms and multi-organ dysfunction. Detailed …

To combat severe acute respiratory syndrome–related coronavirus 2 (SARS-CoV-2) and any
unknown emerging pathogens in the future, the development of a rapid and effective method …

Engineered nanobodies (VHs) to the SARS-CoV-2 receptor-binding domain (RBD) were
generated using phage display technology. A recombinant Wuhan RBD served as bait in …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that
is spreading rapidly, which seriously impacts global public health and economy. Thus …

Accumulating mutations in the SARS-CoV-2 Spike (S) protein can increase the possibility of
immune escape, challenging the present COVID-19 prophylaxis and clinical interventions …

The emergence and global spread of the SARS-CoV-2 Omicron variants, which carry an
unprecedented number of mutations, raise serious concerns due to the reduced efficacy of …

Antibodies against coronavirus spike protein potently protect against infection and disease,
but whether such protection can be extended to variant coronaviruses is unclear. This is …

Antibodies are a principal determinant of immunity for most RNA viruses and have promise
to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 …

A wide range of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
neutralizing monoclonal antibodies (mAbs) have been reported, most of which target the …

The receptor-binding domain (RBD) of the SARS-CoV-2 spike is a primary target of
neutralizing antibodies and a key component of licensed vaccines. Substantial mutations in …